Puma Biotechnology (PBYI) Debt to Equity (2019 - 2025)
Puma Biotechnology's Debt to Equity history spans 7 years, with the latest figure at $0.17 for Q4 2025.
- For Q4 2025, Debt to Equity fell 76.26% year-over-year to $0.17; the TTM value through Dec 2025 reached $0.17, down 76.26%, while the annual FY2025 figure was $0.17, 76.26% down from the prior year.
- Debt to Equity reached $0.17 in Q4 2025 per PBYI's latest filing, down from $0.29 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $13.63 in Q1 2022 to a low of -$39.69 in Q4 2021.
- Average Debt to Equity over 5 years is $0.35, with a median of $1.91 recorded in 2023.
- The largest YoY upside for Debt to Equity was 456.65% in 2021 against a maximum downside of 140.28% in 2021.
- A 5-year view of Debt to Equity shows it stood at -$39.69 in 2021, then skyrocketed by 111.46% to $4.55 in 2022, then crashed by 59.01% to $1.86 in 2023, then crashed by 60.97% to $0.73 in 2024, then tumbled by 76.26% to $0.17 in 2025.
- Per Business Quant, the three most recent readings for PBYI's Debt to Equity are $0.17 (Q4 2025), $0.29 (Q3 2025), and $0.43 (Q2 2025).